StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Deoxycytidine

HCID 13711
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
56905-41-0
Standard-SMILES
Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
InChIKey
CKTSBUTUHBMZGZ-SHYZEUOFSA-N
Summenformel
C9H13N3O4
Durchschnittliche Molmasse
227,22 g/mol
Monoisotopische Masse
227,0906059

Überblick

2'-deoxycytidine is a pyrimidine 2'-deoxyribonucleoside having cytosine as the nucleobase. It has a role as a mouse metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a human metabolite. It is functionally related to a cytosine.

Namen und Bezeichner

Bevorzugter Name
Deoxycytidine
IUPAC
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
Englischer Name
951-77-9
Summenformel
C9H13N3O4
Molmasse
227.22

Namen und Synonyme

2'-deoxycytidine951-77-9deoxycytidineCYTIDINE, 2'-DEOXY-Deoxyribose cytidinedCYDCytosine deoxyribosideDoxecitineDesoxycytidinCytosine, deoxyribonucleoside4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one0W860991D6
Weitere Namen anzeigen
CHEBI:15698DTXSID70883620MT-1621 COMPONENT 2'-DEOXYCYTIDINE4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl)-1,2-dihydropyrimidin-2-one4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl)pyrimidin-2-oneDeoxyriboside, CytosineRefChem:585745

Datenbank-Bezeichner

CAS
56905-41-0、951-77-9
PubChem CID
13711
DTXSID
DTXSID70883620
ChEMBL
CHEMBL66115
ChEBI
CHEBI:15698
UNII
0W860991D6
EC Number
213-454-1
Nikkaji

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-1,8
Polarare Oberfläche (TPSA)
108 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
2
Schwere Atome
16
Formalladung
0
Komplexität
355

Experimentelle und physikochemische Eigenschaften

Chemical ClassesBiological Agents -> Nucleic Acids and Derivatives
DrugsPharmaceuticals -> Listed in ZINC15
LogP-1.77
Solubility870 mg/mL
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point207 - 210 °C
Physical Description · 2 Einträge

White powder; [Sigma-Aldrich MSDS]

Solid

Collision Cross Section · 4 Einträge

158.41 Ų [M+Na]+ [CCS Type: DT; Method: stepped-field]

146.84 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

158.5 Ų [M+K]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

149.1 Ų [M-H]-

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 3 Einträge

This chemical does not meet GHS hazard criteria for 92.3% (12 of 13) of all reports.

Not Classified

Aggregated GHS information provided per 13 reports by companies from 2 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Hazards SummaryMay cause irritation; [Sigma-Aldrich MSDS]
Hazard Classes and CategoriesNot Classified

Chemie und Industrie

Pharmakologische Informationen

Protein BindingIn vitro plasma protein binding of doxecitine was less than 10% over the concentration range between 0.23 mcg/mL and 23 mcg/mL.
Pharmacodynamics · 1 Eintrag

Doxecitine's primary action is a substrate enhancement therapy that corrects the nucleoside imbalance caused by TK2d deficiency. The goal is to provide a high systemic concentration of deoxycytidine and deoxythymidine that can be utilized by unaffected salvage pathways. This action restores the synthesis of mitochondrial DNA (mtDNA) precursors, leading to the restoration of mtDNA copy number and subsequent improvement in respiratory chain enzyme (RCE) activities in affected tissues. This systemic correction counteracts the relentless muscle weakness and respiratory failure characteristic of TK2d, resulting in the amelioration of myopathy, delay of disease onset, and significantly prolonged survival in both preclinical models and patients.

Mechanism of Action · 1 Eintrag

The progressive, often fatal myopathy seen in Thymidine Kinase 2 deficiency (TK2d) is caused by mutations in the nuclear TK2 gene, leading to a dysfunctional or deficient mitochondrial TK2 enzyme. This enzyme is essential for phosphorylating the pyrimidine nucleosides doxecitine (dC) and thymidine (dT) into dCMP and dTMP, which are precursors for the deoxyribonucleotide triphosphates (dNTPs) required for mitochondrial DNA (mtDNA) maintenance and replication. The resulting metabolic block causes severe mtDNA depletion and dysfunction of the mitochondrial respiratory chain.[] Doxecitine, in combination with doxribtimine, functions as a nucleoside substrate enhancement therapy that successfully bypasses the defective mitochondrial pathway. The high concentrations of exogenous dC and dT are primarily phosphorylated by intact cytosolic salvage enzymes, specifically Deoxycytidine Kinase (dCK) and Thymidine Kinase 1 (TK1). The nucleosides are actively transported into cells and across the blood-brain barrier via equilibrative nucleoside transporters. The resulting phosphorylated dNTP precursors are then made available to the mitochondria. This replenishes the critically depleted dNTP pools, which facilitates the replication of mtDNA by the mitochondrial DNA Polymerase gamma.

Biological Half-LifeThe mean half-life was approximately 1 hour for doxecitine following a single oral administration of 133 mg/kg doxecitine under fed conditions in healthy adult subjects.

Zugehörige Reaktionen

25
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1725
HRID 1725als Edukt
Reaktionsgleichung von HRID 25468
HRID 25468als Edukt
Reaktionsgleichung von HRID 84065
HRID 84065als Edukt
Reaktionsgleichung von HRID 366970
HRID 366970als Edukt
Reaktionsgleichung von HRID 366972
HRID 366972als Edukt
Reaktionsgleichung von HRID 600111
HRID 600111als Edukt
Reaktionsgleichung von HRID 844537
HRID 844537als Produkt
Reaktionsgleichung von HRID 844538
HRID 844538als Produkt
ZurückSeite 1 von 4

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
J14.406A
Metabolism/Metabolites · 1 Eintrag

Doxecitine is primarily degraded by cytidine deaminase to its nucleobases and the 2-deoxy-α-D-ribose 1-phosphate moiety. Intermediate products of doxecitine catabolism are deoxyuridine, uracil, and dihydrouracil with the end products β-alanine, ammonia, and carbon dioxide (CO2).

Absorption, Distribution and Excretion · 2 Einträge

Doxecitine is administered orally, with rapid absorption and plasma concentrations returning to near baseline within 8 to 12 hours. The absolute bioavailability of doxecitine following oral administration has not been determined. The median time to peak plasma concentration (Tmax) was approximately two hours for doxecitine.

Urinary excretion of intact doxecitine and doxribtimine was <1% of the dose in healthy subjects following an oral administration of doxecitine and doxribtimine.

Tissue LocationsAll Tissues
Cellular LocationsExtracellular
Metabolite PathwaysBeta Ureidopropionase Deficiency

Verwendung und Herstellung

General Manufacturing InformationCytidine, 2'-deoxy-: ACTIVE